Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALDH1/3 inhibitor ABD-3001

A suicidal inhibitor of aldehyde dehydrogenases 1 (ALDH1) and 3 (ALDH3), with potential antineoplastic activity. Upon administration, ALDH1/3 inhibitor ABD-3001 targets, binds to and irreversibly inhibits the activity of ALDH1 and ALDH3. This results in the accumulation of reactive aldehydes in tumor cells, which interferes with oncogenic signaling pathways and tumor cell proliferation. In addition, the inhibition of ALDH1 and ALDH3 disrupts glutathione redox balance in tumor cells, leading to oxidative stress which may further promote tumor cell death.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	DIMATE dimethyl ampal thiolester
Code name:	ABD 3001 ABD-3001 ABD3001

ALDH1/3 inhibitor ABD-3001

Search NCI's Drug Dictionary